Literature DB >> 7772518

Bone marrow pathology in relapsing polychondritis: high frequency of myelodysplastic syndromes.

L Diebold1, G Rauh, K Jäger, U Löhrs.   

Abstract

Haemopathologic changes were studied in 19 patients (13 male, six female, age 33-85 years, mean 56 years) with relapsing polychondritis (RP). Anaemia was found in eight, thrombocytopenia in two and splenomegaly in three patients. A total of 17 bone marrow biopsies were obtained from seven individuals. Bone marrow evaluation revealed myelodysplastic syndromes (MDS) with marked trilineage hyperplasia and dysplasia in three cases. Since an excess of myeloblasts or an increase of CD34 positive progenitor cells was not seen, the disorders were designated as 'refractory anaemia' or with regard to the dysplastic megakaryopoiesis 'MDS, unclassifiable'. Two of the three patients died after 10 and 55 months of follow-up due to infectious complications. In a further patient, bone marrow analysis repeatedly showed an unexplained granulopoietic hyperplasia, which, however, was not dysplastic enough to allow a diagnosis of MDS. The remaining patients had clearly reactive changes. Our findings support the notion that RP is a heterogenous disorder and suggest that RP may at times represent a paraneoplastic phenomenon of an underlying MDS. Since HLA typing revealed a significantly increased frequency of the antigen DR4 (10/17 patients positive = 59%), we hypothesize that immunological imbalances due to the MDS in conjunction with a specific immunogenetic background may play key roles in the pathogenesis of RP in these patients.

Entities:  

Mesh:

Year:  1995        PMID: 7772518     DOI: 10.1111/j.1365-2141.1995.tb08420.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Sweet's syndrome after adalimumab therapy for refractory relapsing polychondritis.

Authors:  Sarah Keidel; Aubretia McColl; Sally Edmonds
Journal:  BMJ Case Rep       Date:  2011-12-21

2.  Total hearing loss and blindness caused by relapsing polychondritis and myelodysplastic syndrome.

Authors:  Bozena Coha; Ljubica Fustar-Preradovic; Sandra Sekelj; Alen Sekelj
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-07-17       Impact factor: 2.503

3.  Polychondritis Terminating in Eosinophilic Leukemia.

Authors:  Judit Várkonyi; Lajos Jakab; Attila Zalatnay; Péter Nagy; Rita Vámoss; Tamás Szombathy
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

4.  Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.

Authors:  Mohamed-Yacine Khitri; Alexis F Guedon; Sophie Georgin-Lavialle; Benjamin Terrier; David Saadoun; Julie Seguier; Maelle le Besnerais; Claire De Moreuil; Guillaume Denis; Mathieu Gerfaud-Valentin; Jean Sebastien Allain; Alexandre Maria; Laurence Bouillet; Vincent Grobost; Joris Galland; Olivier Kosmider; Anael Dumont; Mathilde Devaux; Benjamin Subran; Jean Schmidt; Paola Marianetti-Guingel; Sylvain Audia; Sylvain Palat; Marielle Roux-Sauvat; Vincent Jachiet; Pierre Hirsch; Olivier Fain; Arsène Mekinian
Journal:  RMD Open       Date:  2022-07

5.  A case of relapsing polychondritis associated with myelodysplastic syndrome with erythroid hypoplasia/aplasia.

Authors:  Seong-Wook Heo; Kyu-Hyun Cho; Jung-Il Ryu; Seung-Hie Chung; Chae-Gi Kim; Sang-Gyung Kim; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.